Monday, March 28, 2016

President of Q BioMed Inc. Expands on Corporate Update in Q&A


President of Q BioMed Inc. Expands on Corporate Update in Q&A

 

Denis Corin Discusses Mannin Research Inc’s Leading Glaucoma Drug Candidate MAN-01

 

 

March 21 , 2016 Point Roberts WA -  Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases a recent interview with Mr. Denis Corin, President of Q BioMed Inc. (OTCQB:QBIO).  Denis expands on the recent corporate update and Scrip Intelligence Video released in late February. He also comments on recent developments with Mannin Research Inc’s leading glaucoma drug candidate MAN-01.  (In October 2015 Q BioMed Inc. entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics.)

 

Q&A
Q: Investorideas.com

Denis, your company’s strategy is to acquire companies and biomedical assets. Can you expand on that and also share what assets have been acquired or licensed to date?

 

A: Mr. Denis Corin, President of Q BioMed Inc.

Sure, our mission is to license and acquire innovative life sciences assets from academia or small private companies and provide the strategic resources including financial capital, intellectual capital, business development and scientific advice to accelerate their product development timelines to commercialize their drug candidates or bring them to the next level in terms of valuation inflection.

 

We have identified several targets that we believe could provide a substantial pipeline of innovative and high value assets. We will aim to maximize risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle, so we’ll have assets in pre-clinical, clinical and commercial stages. This allows a nice flow of development news and value drivers as they all move through their paces. We expect to benefit from early positioning in illiquid and/or unknown private assets with multiple potential products in their development cycle and to capitalize on valuation growth as they move forward in their development. We believe this gives investors a unique opportunity to participate in the growth and development of these assets and the value they bring to the overall pipeline.

 

In the last quarter of 2015, we entered into an exclusive License and Purchase Option Agreement with Mannin Research Inc. whereby we were granted a worldwide, exclusive license, with the option to acquire their platform assets for Glaucoma and other indications. The Mannin IP and technology platform is initially focused on developing a first-in-class eye drop treatment for glaucoma. The technology platform may be expanded in scope beyond Glaucoma as well as beyond ophthalmological uses and may include cystic kidney disease and others.

 

This is an area of therapy that urgently needs a new offering. No new drugs in this particular indication have been successfully brought to this market for over 20 years.

 

The global market for Glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market.  There are 60 million people worldwide suffering from Glaucoma.  It is projected that the total population suffering from Glaucoma will grow to 80 million by 2020 (W.H.O 2010), so there is an acute need for this type of drug in a very lucrative market. Our lead candidate, MAN-01, will address this market as a first-in-class drug that treats abnormal vessels within the eye, thereby treating Glaucoma at its root causes. 

 

There is no cure for Glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients.

 

Together with Mannin, we are developing a unique molecule in the form of an easy-to-administer eye drop, designed to repair the normal flow of fluid in the eye and resulting in the reduction of intraocular pressure (IOP), one of the main causes of Glaucoma. Our platform is both unique and first-in-class and we are the only drug company targeting this method of action.

 

IOP caused by abnormal flow of clear fluid within the eye damages the nerves in the eye, eventually leading to blindness. A specialized blood vessel, the ‘Schlemm’s Canal’ is the major drainage pathway for fluid to escape from the front of the eye. Glaucoma can occur when this canal is either blocked or from a birth defect, resulting in a small or absent Schlemm’s Canal. Our drug candidate would target the organization of the Schlemms Canal on a cellular level, thereby creating the optimal environment for ‘repair’ and improved flow and ultimately, lower IOP.

 

Given the large 23 Billion dollar ophthalmology market and the acute need for these types of drugs, we believe there is a substantial opportunity here. In addition, a deep pipeline of novel therapeutics can be developed from this research platform, developed and lead by Dr. Quaggin, which would treat a spectrum of vascular diseases including Cystic Kidney disease.

 

So to sum up, while this is an earlier stage pre-clinical asset, we see tremendous opportunity here and look forward to building value in it as we advance.

 

 

Q: Investorideas.com

Can you tell us about your recent addition to management, Mr. David Laskow-Pooley, as VP Scientific & Product Development, and the value added to your team in seeking new products for your pipeline?

 

A: Mr. Denis Corin, President of Q BioMed Inc.

David is an industry veteran with a very broad-based and deep knowledge. We are very pleased to have him on board with us. He has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics.

 

David brings tremendous operational value to us as we look at commercializing assets and advancing them through the development life cycle. He has some very deep and unique experiences that will fit perfectly with some of the assets we are currently evaluating.

 

 

Q: Investorideas.com

Can you talk about Mannin Research Inc’s Glaucoma treatment technology and its lead drug candidate MAN-01 and the progress it is making?

 

A: Mr. Denis Corin, President of Q BioMed Inc

Mannin Research’s (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, we aim to use it in the clinic in late 2017/early 2018. There we are looking at demonstrating the effectiveness of this therapeutic in lowering intraocular pressure (IOP). We are making good progress and are on track to meet our internal milestones.

 

 

Q: Investorideas.com

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) reported safety results recently from a trial testing its Glaucoma treatment. Can you give us a quick differentiation in technology and approach between Mannin’s MAN-01 and Aerie Pharmaceuticals treatment?


A: Mr. Denis Corin, President of Q BioMed Inc.

 Aerie’s approach to treatment in Glaucoma, like ours, is to reduce IOP, which is the gold standard in measuring the effectiveness of Glaucoma’s therapeutics. Aerie’s mechanism of action (MOA) is the Rock/NET pathway which acts primarily on the Tubercular Meshwork, best described as a ‘sieve’ that sits on top of the main drainage canal in the eye, the ‘Schlemms Canal’. If this ‘sieve’ becomes inelastic or degraded it inhibits the optimal flow of fluids to the drain. Imagine, if you will, a ‘leaf-guard’ on top of a gutter on the roof of your house.

 

Mannin’s approach is to reduce IOP by addressing the defective cellular makeup of the actual ‘drain or gutter’ responsible for 70-90% of the fluid movement. Just a small improvement in the performance of this important vessel can have a significant effect on fluid movement and reducing IOP. So we believe this is a very important area for therapeutic development which is currently not being addressed with existing or new therapeutics in the pipeline.

 

The technical description of this is described in Dr. Quaggin’s research published in the JCI 2014 paper (Thompson et all, JCI, 2014).

 

Q: Investorideas.com

In your recent update you stated it is your goal to have at least 3 asset transactions completed this year to expand and broaden your pipeline. Can you tell us what areas within your sector seem promising and what you are looking into?

 

A: Mr. Denis Corin, President of Q BioMed Inc.

We are not really looking in any area specifically. We are just hunting for good value in undervalued or undiscovered assets that we believe have great potential. That said, we have a few targets on our due diligence list now that we really like. The most likely to make the top of that short list is a revenue ready asset that we think could be a revenue generator in the first year and also has some very exciting indication expansion possibilities. We’d like to have one deal done in the next quarter and possibly one more by the end of the year.

 

We hope interested shareholders and potential shareholders will stay up to date on our progress and come along for the ride by visiting our website and sign up for out news updates.

 

 

About Q BioMed Inc. ( OTCQB:QBIO)

Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.




About Investorideas.com - Big Ideas for Global Investors

InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas



Sign up for free news alerts at Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

 

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

 

Contact Investorideas.com

800 665 0411

No comments: